Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Abstract

Subtype-specific antibodies for muscarinic cholinergic receptors. II. Studies with reconstituted chick heart receptors and the GTP-binding protein G(o).

R M Richardson, C S Mayanil and M M Hosey
Molecular Pharmacology December 1991, 40 (6) 908-914;
R M Richardson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C S Mayanil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M M Hosey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The antibodies described in the accompanying paper were used to probe the interactions of the chick heart muscarinic acetylcholine receptors (mAChRs) with the GTP-binding protein G(o). The anti-m4b antibodies, which were made against a peptide from the amino-terminal portion of the third cytoplasmic loop of the m4 mAChR subtype, were tested for their abilities to affect the coupling of the chick heart mAChR to the GTP-binding protein G(o). The purified chick heart mAChRs were reconstituted with purified G(o) in phospholipid vesicles, and their interactions were monitored in the presence or absence of the antibodies. The anti-m4b antibodies completely inhibited the ability of G(o) to promote high affinity agonist binding to the purified receptors. The anti-m4b antibodies also completely inhibited the agonist-stimulated binding of guanosine-5'-O-(3-thio)triphosphate (GTP gamma S) to G(o) and the receptor-stimulated GTPase activity of G(o). These findings indicate that the amino-terminal portion of the third cytoplasmic loop is an important determinant for G(o) to promote high affinity agonist binding to the chick heart mAChR and also for the agonist-stimulated GTP gamma S binding and GTPase activity. The anti-m4a, anti-m2, and anti-m1a antibodies, which were made against centrally located peptides of the third cytoplasmic loop of the m4, m2, and m1 mAChR subtypes, respectively, were also tested for their effects in the reconstituted receptor/G(o) system. The anti-m2 and anti-m4a antibodies also significantly reduced agonist-stimulated GTP gamma S binding, as well as GTPase activity, but did not completely abolish these functions, as was the case with anti-m4b antibodies. However, the anti-m4a and anti-m2 antibodies shared with anti-m4b antibodies the ability to markedly inhibit the ability of G(o) to promote high affinity agonist binding to the purified and reconstituted receptors. In contrast to the results obtained with the anti-m2 and anti-m4 antibodies, the anti-m1a antibodies had smaller effects on the receptor/G(o) interactions. These results suggested that central portions of the loop can also influence mAChR/G(o) interactions. Studies were als performed to test the effects of the peptides that were used as antigens on receptor-mediated GTP gamma S binding to G(o). Each of the peptides caused significant inhibition of this function, but the greatest inhibition was observed with the m4b peptide. In sum, the results suggest that multiple domains in the third cytoplasmic loop of chick heart mAChR can modulate interactions with G(o).

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 40, Issue 6
1 Dec 1991
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Subtype-specific antibodies for muscarinic cholinergic receptors. II. Studies with reconstituted chick heart receptors and the GTP-binding protein G(o).
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Subtype-specific antibodies for muscarinic cholinergic receptors. II. Studies with reconstituted chick heart receptors and the GTP-binding protein G(o).

R M Richardson, C S Mayanil and M M Hosey
Molecular Pharmacology December 1, 1991, 40 (6) 908-914;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Abstract

Subtype-specific antibodies for muscarinic cholinergic receptors. II. Studies with reconstituted chick heart receptors and the GTP-binding protein G(o).

R M Richardson, C S Mayanil and M M Hosey
Molecular Pharmacology December 1, 1991, 40 (6) 908-914;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics